Incruse Ellipta is intended as a once-daily maintenance treatment to be administered via GSK’s Ellipta inhaler.
GSK plans to begin distributing the drug in the fourth quarter of this year.
More Articles on FDA Approvals:
FDA Grants Accelerated Approval to Lung Cancer Treatment Drug
FDA Approves DNA Test for Primary Cervical Cancer Screening
FDA Approves First Drug to Treat Castleman’s Disease
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.